NO20020663L - NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft - Google Patents

NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft

Info

Publication number
NO20020663L
NO20020663L NO20020663A NO20020663A NO20020663L NO 20020663 L NO20020663 L NO 20020663L NO 20020663 A NO20020663 A NO 20020663A NO 20020663 A NO20020663 A NO 20020663A NO 20020663 L NO20020663 L NO 20020663L
Authority
NO
Norway
Prior art keywords
bowel
nsaid
inhibition
treatment
kinase inhibitor
Prior art date
Application number
NO20020663A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020663D0 (no
Inventor
Philip Frost
Carolyn Discafani-Marro
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of NO20020663D0 publication Critical patent/NO20020663D0/no
Publication of NO20020663L publication Critical patent/NO20020663L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20020663A 1999-08-12 2002-02-11 NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft NO20020663L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (2)

Publication Number Publication Date
NO20020663D0 NO20020663D0 (no) 2002-02-11
NO20020663L true NO20020663L (no) 2002-04-09

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020663A NO20020663L (no) 1999-08-12 2002-02-11 NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft

Country Status (24)

Country Link
EP (1) EP1202746B1 (enExample)
JP (1) JP2003507342A (enExample)
KR (1) KR20020018201A (enExample)
CN (1) CN1229142C (enExample)
AR (1) AR029763A1 (enExample)
AT (1) ATE341341T1 (enExample)
AU (1) AU783116B2 (enExample)
BR (1) BR0013219A (enExample)
CA (1) CA2380904C (enExample)
CZ (1) CZ2002474A3 (enExample)
DE (1) DE60031127T2 (enExample)
DK (1) DK1202746T3 (enExample)
EA (1) EA006876B1 (enExample)
ES (1) ES2272305T3 (enExample)
HK (1) HK1042244A1 (enExample)
HU (1) HUP0203162A3 (enExample)
IL (1) IL147913A0 (enExample)
MX (1) MXPA02001448A (enExample)
NO (1) NO20020663L (enExample)
NZ (1) NZ517120A (enExample)
PL (1) PL353267A1 (enExample)
PT (1) PT1202746E (enExample)
WO (1) WO2001012227A1 (enExample)
ZA (1) ZA200201156B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
BR0109165A (pt) * 2000-03-13 2003-04-22 American Cyanamid Co Método de tratamento de pólipos colÈnicos
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
EP1409481B1 (en) 2001-07-16 2006-10-04 Astrazeneca AB Quinoline derivatives and their use as tyrosine kinase inhibitors
DE60224299T2 (de) * 2001-10-25 2008-12-11 Novartis Ag Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1542989B1 (en) 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1551824B1 (en) 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
EP1758601A1 (en) 2004-06-03 2007-03-07 F.Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
US20120064072A1 (en) 2009-03-18 2012-03-15 Maryland Franklin Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
RU2606114C2 (ru) * 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Новые модуляторы иммунной системы

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001521926A (ja) * 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
EP1039910A1 (en) * 1997-11-06 2000-10-04 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps

Also Published As

Publication number Publication date
ES2272305T3 (es) 2007-05-01
CZ2002474A3 (cs) 2003-02-12
EA006876B1 (ru) 2006-04-28
AR029763A1 (es) 2003-07-16
PT1202746E (pt) 2007-01-31
NO20020663D0 (no) 2002-02-11
EP1202746B1 (en) 2006-10-04
AU6395900A (en) 2001-03-13
HUP0203162A2 (hu) 2003-01-28
HK1042244A1 (zh) 2002-08-09
CA2380904C (en) 2009-02-10
IL147913A0 (en) 2002-08-14
EP1202746A1 (en) 2002-05-08
WO2001012227A1 (en) 2001-02-22
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
HUP0203162A3 (en) 2006-07-28
ZA200201156B (en) 2003-05-12
EA200200246A1 (ru) 2002-08-29
ATE341341T1 (de) 2006-10-15
KR20020018201A (ko) 2002-03-07
DK1202746T3 (da) 2007-01-02
PL353267A1 (en) 2003-11-03
CN1229142C (zh) 2005-11-30
BR0013219A (pt) 2002-04-23
DE60031127D1 (de) 2006-11-16
NZ517120A (en) 2004-10-29
CN1370080A (zh) 2002-09-18
JP2003507342A (ja) 2003-02-25
DE60031127T2 (de) 2007-02-01
MXPA02001448A (es) 2002-07-02

Similar Documents

Publication Publication Date Title
NO20020663D0 (no) NSAID og EFGR kinase inhibitor inneholdende sammensetning for behandling eller inhibisjon av tarmpolypper og tarmkreft
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
NO20002166D0 (no) Anvendelse av quinazolinderivater som tyrosinkinaseinhibitorer for behandling av kolonpolypper
NO20021587D0 (no) Sementeringsblandinger og bruk av slike blandinger for sementering av brönner eller lignende
NO20013380D0 (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO20015797L (no) Indazolforbindelser og farmasöytiske forbindelser for inhibering av proteinkinaser, og fremgangsmåter til anvendelsederav
NO20025792L (no) Kinazolinderivater for behandling av tumorer
IL151249A0 (en) Use of cyanoquinolines for treating or inhibiting colonic polyps
NO20014379L (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO20024386D0 (no) Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
NO20025307D0 (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose
NO20020365L (no) Oligonukleotider for inhibiering av ekspresjonen av humant eg5
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
IS5772A (is) Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum
NO993784D0 (no) Farmasöytiske blandinger inneholdende ibuprofen og domperidon for behandling av migrene
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
NO20012428D0 (no) Substituerte kaprolaktamer, farmasöytiske sammensetninger som inneholder dem og deres anvendelse ved behandling av tumorer
PT1263421E (pt) Avasimibe, o inibidor duplo da sintese de ester de colesterilo e de ester ceroso, para o tratamento de disturbios da glandula sebacea
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
NO20035299D0 (no) Preparater og syklooksygenase-2-selektive inhibitorer og bestråling for inhibering eller forhindring av kardiovaskul¶re sykdommer
NO20003199D0 (no) Benzo(C)kinolizinderivater og deres anvendelse som 5- <alfa>reduktaseinhibitorer
SI1202746T1 (sl) FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application